Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17502798 | 1.00 | TDP1 (0.49) | TDP1L3MBTL1ATMPPARGBCHE | |
| SCHEMBL30605965 | 1.00 | TDP1 (0.49) | TDP1L3MBTL1ATMPPARGBCHE | |
| SCHEMBL3632860 | 0.93 | TDP1 (0.44) | TDP1L3MBTL1ATMPPARGBCHE | |
| Methyl Alcohol SCHEMBL27966192 | 0.91 | ADRB2 (0.43) | TDP1L3MBTL1ATMPPARGBCHE | |
| Water SCHEMBL27298765 | 0.91 | L3MBTL1 (0.43) | TDP1L3MBTL1ATMPPARGBCHE | |
| SCHEMBL27915693 | 0.88 | L3MBTL1 (0.48) | TDP1L3MBTL1ATMADRB2ADRB1 | |
| SCHEMBL27726032 | 0.88 | TDP1 (0.49) | TDP1L3MBTL1ATMPPARGBCHE | |
| SCHEMBL1826831 | 0.86 | TDP1 (0.47) | TDP1L3MBTL1ATMPPARGBCHE | |
| SCHEMBL27517150 | 0.86 | CASP1 (0.42) | TDP1L3MBTL1ATMPPARGBCHE | |
| SCHEMBL1261877 | 0.84 | MEN1 (0.51) | TDP1L3MBTL1ATMPPARGBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270184-A1 | PROCESSES FOR THE PREPARATION OF FINERENONE | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2025-08-28 | — | — | US | disclosed |
| US-20240316052-A1 | MITOCHONDRIAL SUPERCOMPLEX FORMATION PROMOTER, COMPOSITION FOR MAINTAINING OR IMPROVING MUSCULAR STRENGTH, THERAPEUTIC OR PREVENTATIVE PHARMACEUTICAL COMPOSITION FOR DISEASES WHICH DECREASE MITOCHONDRIAL FUNCTION OR MUSCULAR FUNCTION, AND SCREENING METHOD FOR SUBSTANCES WHICH CONTRIBUTE TO FORMATION OF MITOCHONDRIAL SUPERCOMPLEX | TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY (JP) | 2024-09-26 | — | — | US | disclosed |
| WO-2016108206-A2 | PROCESSES FOR PREPARATION OF IDELALISIB AND INTERMEDIATES THEREOF | DR. REDDY’S LABORATORIES LIMITED (IN) | 2016-07-07 | — | — | WO | disclosed |
| CN-102351918-B | Glucopyranosyl-substituted benzonitrile derivatives and pharmaceutical compositions containing the same | BOEHRINGER INGELHEIM INT | 2015-03-04 | — | — | CN | disclosed |
| CN-103601709-A | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INT | 2014-02-26 | — | — | CN | disclosed |
| CN-101939316-B | Spirocyclic heterocyclic compounds, medicaments containing said compounds, their use and processes for their preparation | BOEHRINGER INGELHEIM INT | 2013-10-02 | — | — | CN | disclosed |
| CN-102351918-A | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing said compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INT | 2012-02-15 | — | — | CN | disclosed |
| CN-102203064-A | Novel benzamides, their preparation and their use as medicaments | BOEHRINGER INGELHEIM INT | 2011-09-28 | — | — | CN | disclosed |
| US-7544840-B2 | Method of production of (−)-(S)-3-[1-(dimethylamino)ethyl]phenyl-N-ethyl-N-methylcarbamate | ZENTIVA, A.S. (CZ) | 2009-06-09 | — | — | US | disclosed |
| CN-101437807-A | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing said compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INT (DE) | 2009-05-20 | — | — | CN | disclosed |
| EP-1556338-A1 | A METHOD OF PRODUCTION OF (-)-(S)-3- 1-(DIMETHYLAMINO)ETHYL& rsqb;PHENYL-N-ETHYL-N-METHYLCARBAMATE | Zentiva, A.S. (CZ) | 2005-07-27 | — | — | EP | disclosed |
| CN-1183127-C | Alkoxy-substituted benzimidazole compounds, pharmaceutical formulations containing them and methods of using them | — | 2005-01-05 | — | — | CN | disclosed |
| CN-1509270-A | Indolinones substituted in the 6-position, process for their preparation and their use as kinase inhibitors | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-06-30 | — | — | CN | disclosed |
| WO-2004037771-A1 | A METHOD OF PRODUCTION OF (-)-(S)-3-[1-(DIMETHYLAMINO)ETHYL]PHENYL-N-ETHYL-N-METHYLCARBAMATE | ZENTIVA, A.S. (CZ) | 2004-05-06 | — | — | WO | disclosed |
| CN-1384831-A | Alkoxy-substituted benzimidazole compounds, pharmaceutical formulations containing them and methods of using them | EIPHAVMA INC (US) | 2002-12-11 | — | — | CN | disclosed |
| CN-1319090-A | Novel substuted indolimones, their preparation process and use as medicine | BOEHRINGER INGELHEIM PHARMA (DE) | 2001-10-24 | — | — | CN | disclosed |
| CN-1066445-C | Aroyl-piperidine derivatives | NOVARTIS AG (CH) | 2001-05-30 | — | — | CN | disclosed |
| CN-1187186-A | Substituted phenyl amindines, medicaments containing these compounds and process for producing them | THOMAE GMBH DR K (DE) | 1998-07-08 | — | — | CN | disclosed |
| CN-1133839-A | Aroyl-piperidine derivatives | CIBA GEIGY AG (CH) | 1996-10-23 | — | — | CN | disclosed |
| CN-1087904-A | Carboxylic acid derivative, the pharmaceutical composition that contains these compounds with and preparation method thereof | KRAL THOMAE GMBH (DE) | 1994-06-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270184-A1 | PROCESSES FOR THE PREPARATION OF FINERENONE | CYP11B1, CYP11B2, HSD17B7 | TDP1 1814/4885L3MBTL1 4788/4885ATM 828/4885 |
| US-20240316052-A1 | MITOCHONDRIAL SUPERCOMPLEX FORMATION PROMOTER, COMPOSITION FOR MAINTAINING OR IMPROVING MUSCULAR STRENGTH, THERAPEUTIC OR PREVENTATIVE PHARMACEUTICAL COMPOSITION FOR DISEASES WHICH DECREASE MITOCHONDRIAL FUNCTION OR MUSCULAR FUNCTION, AND SCREENING METHOD FOR SUBSTANCES WHICH CONTRIBUTE TO FORMATION OF MITOCHONDRIAL SUPERCOMPLEX | TFAM, MAVS, CKMT1A; CKMT1B | TDP1 408/4885L3MBTL1 4102/4885ATM 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.